High-affinity urokinase-derived cyclic peptides inhibiting urokinase/urokinase receptor-interaction: Effects on tumor growth and spread

FEBS Letters

Volumn 528, Issue 1-3, 2002, Pages 212-216

  Sato, Sumito ^a   Kopitz, Charlotte ^b   Schmalix, Wolfgang A ^c   Muehlenweg, Bernd ^c   Kessler, Horst ^b   Schmitt, Manfred ^a   Krüger, Achim ^b   Magdolen, Viktor ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Wilex Biotechnology GmbH   (Germany)

Author keywords

Cancer; Competitive uPA derived peptide antagonists; Urokinase type plasminogen activator

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPEPTIDE; PLASMINOGEN ACTIVATOR INHIBITOR; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR; WX 360; WX 360 NLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; OVARY CARCINOMA; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TUMOR; WEIGHT;

ANIMALS; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; RECEPTORS, CELL SURFACE; TRANSPLANTATION, HETEROLOGOUS; URINARY PLASMINOGEN ACTIVATOR;

MUS MUSCULUS;

EID: 0037174147     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-5793(02)03311-2     Document Type: Article

References (27)

1. Reuning U., Magdolen V., Wilhelm O., Fischer K., Lutz V., Graeff H., Schmitt M. Int. J. Oncol. 13:1998;893-906.
2. Andreasen P.A., Egelund R., Petersen H.H. Cell. Mol. Life Sci. 57:2000;25-40.
3. Schmitt M., Wilhelm O., Reuning U., Krüger A., Harbeck N., Lengyel E., Graeff H., Gänsbacher B., Kessler H., Bürgle M., Stürzebecher J., Sperl S., Magdolen V. Fibrinol. Proteol. 14:2000;114-132.
4. Muehlenweg B., Sperl S., Magdolen V., Schmitt M., Harbeck N. Expert Opin. Biol. Ther. 1:2001;683-691.
5. Del Rosso M., Fibbi G., Pucci M., D'Alessio S., Del Rosso A., Magnelli L., Chiarugi V. Clin. Exp. Metastasis. 19:2002;193-207.
6. Ellis V., Scully M.F., Kakkar V.V. J. Biol. Chem. 264:1989;2185-2188.
7. Bürgle M., Koppitz M., Riemer C., Kessler H., König B., Weidle U.H., Kellermann J., Lottspeich F., Graeff H., Schmitt M., Goretzki L., Reuning U., Wilhelm O., Magdolen V. Biol. Chem. 378:1997;231-237.
8. Magdolen V., Bürgle M., Arroyo de Prada N., Schmiedeberg N., Riemer C., Schroeck F., Kellermann J., Degitz K., Wilhelm O.G., Schmitt M., Kessler H. Biol. Chem. 382:2001;1197-1205.
9. Guthaus E., Bürgle M., Schmiedeberg N., Hocke S., Eickler A., Kramer M.D., Sweep C.G., Magdolen V., Kessler H., Schmitt M. Biol. Chem. 383:2002;207-216.
10. Schmiedeberg, N., Bürgle, M., Wilhelm, O., Lottspeich, F., Graeff, H., Schmitt, M., Magdolen, V. and Kessler, H. (2000) in: Peptides for the New Millennium, Proceedings of the Sixteenth American Peptide Symposium (Fields, G.B., Tam, J.P. and Barany, G., Eds.), pp. 543-545, Kluwer Academic Publishers, Dordrecht.
11. Schmiedeberg, N., Schmitt, M., Rölz, C., Truffault, V., Sukopp, M., Bürgle, M., Wilhelm, O.G., Schmalix, W., Magdolen, V. and Kessler, H. (2002) J. Med. Chem., in press.
12. Krüger A., Soeltl R., Lutz V., Wilhelm O.G., Magdolen V., Rojo E.E., Hantzopoulos P.A., Graeff H., Gänsbacher B., Schmitt M. Cancer Gene Ther. 7:2000;292-299.
13. Lutz V., Reuning U., Krüger A., Luther T., Plidner von Steinburg S., Graeff H., Schmitt M., Wilhelm O.G., Magdolen V. Biol. Chem. 382:2001;789-798.
14. Möbus V.J., Moll R., Gerharz C.D., Kieback D.G., Weikel W., Hoffmann G., Kreienberg R. Br. J. Cancer. 69:1994;422-428.
15. Krüger A., Schirrmacher V., Khokha R. Cancer Metastasis Rev. 17:1999;285-294.
16. Fischer K., Lutz V., Wilhelm O., Schmitt M., Graeff H., Heiss P., Nishiguchi T., Harbeck N., Kessler H., Luther T., Magdolen V., Reuning U. FEBS Lett. 438:1998;101-105.
17. Krüger A., Schirrmacher V., von Hoegen P. Int. J. Cancer. 58:1994;275-284.
18. Sperl S., Mueller M., Wilhelm O.G., Schmitt M., Magdolen V., Moroder L. Drug News Perspect. 14:2002;401-411.
19. Ploug M., Gårdsvoll H., Jorgensen T.J., Lonborg Hansen L., Danø K. Biochem. Soc. Trans. 30:2002;177-183.
20. Crowley C.W., Cohen R.L., Lucas B.K., Lui G., Shuman M., Levinson A.D. Proc. Natl. Acad. Sci. USA. 90:1993;5021-5025.
21. Min H.Y., Doyle L.V., Vitt C.R., Zandonella C.L., Stratton-Thomas J.R., Shuman M.A., Rosenberg S. Cancer Res. 56:1996;2428-2433.
22. Quax P.H., Lamfers M.L., Lardenoye J.H., Grimbergen J.M., de Vries M.R., Slomp J., de Ruiter M.C., Kockx M.M., Verheijen J.H., van Hinsbergh V.W. Circulation. 103:2001;562-569.
23. Kobayashi H., Sugino D., She M.Y., Ohi H., Hirashima Y., Shinohara H., Fujie M., Shibata K., Terao T. Eur. J. Biochem. 253:1998;817-826.
24. Goodson R.J., Doyle M.V., Kaufman S.E., Rosenberg S. Proc. Natl. Acad. Sci. USA. 91:1994;7129-7133.
25. Tressler R.J., Pitot P.A., Stratton J.R., Forrest L.D., Zhuo S., Drummond R.J., Fong S., Doyle M.V., Doyle L.V., Min H.Y., Rosenberg S. APMIS. 107:1999;168-173.
26. Guo Y., Higazi A.A., Arakelian A., Sachais B.S., Cines D., Goldfarb R.H., Jones T.R., Kwaan H., Mazar A.P., Rabbani S.A. FASEB J. 14:2000;1400-1410.
27. Ploug M., Ostergaard S., Gårdsvoll H., Kovalski K., Holst-Hansen C., Holm A., Ossowski L., Danø K. Biochemistry. 40:2001;12157-12168.